Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: A preliminary study (METRO)

Shamanna S. Iyengar, G. M C Rosano

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Although antianginal drugs are used over several months and through to years in stable angina, there is scant evidence regarding their influence on outcomes. The METRO (ManagEment of angina: a reTRospective cOhort) study sought to assess the independent effect of using these drugs on subsequent mortality risk in patients with stable angina. Methods: Consecutive patients with stable angina, receiving at least one antianginal drug (nitrates, β-adrenoceptor antagonists, calcium channel antagonists, trimetazidine, or nicorandil), were selected if they were discharged alive from an intensive care unit following a myocardial infarction (MI). Their case-record data were used in a multivariate logistic regression model to examine the independent association of antianginal drug use prior to the MI with predicted post-discharge, 6-month, all-cause mortality risk. Results: In 353 patients, of whom 287 (81.3%) were men, the mean (± SD) age was 55 (± 10.2) years and duration of treated stable angina was 27.2 (± 24.8) months. The odds ratios (95% CI) of 6-month, all-cause mortality after surviving an MI were: for treatment that included a β-adrenoceptor antagonist, 0.63 (0.26, 1.52; p = 0.309); a calcium channel antagonist, 0.76 (0.12, 2.89; p = 0.638); a nitrate, 0.52 (0.26, 1.05; p = 0.070); nicorandil, 0.62 (0.29, 1.33; p = 0.221); and trimetazidine, 0.36 (0.15, 0.86; p = 0.022). Conclusion: The inclusion of trimetazidine in the antianginal treatment of stable angina is independently associated with a significant reduction in mortality after surviving an MI. This suggests that combining a metabolic agent with drugs that modulate oxygen supply and demand, early in the management of stable angina, may confer a survival benefit.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalAmerican Journal of Cardiovascular Drugs
Volume9
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Stable Angina
Myocardial Infarction
Trimetazidine
Mortality
Pharmaceutical Preparations
Nicorandil
Calcium Channel Blockers
Nitrates
Adrenergic Receptors
Logistic Models
Intensive Care Units
Cohort Studies
Retrospective Studies
Odds Ratio
Oxygen
Survival
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{0cb4e4aff4f748b28d96e4a86ce795da,
title = "Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: A preliminary study (METRO)",
abstract = "Background: Although antianginal drugs are used over several months and through to years in stable angina, there is scant evidence regarding their influence on outcomes. The METRO (ManagEment of angina: a reTRospective cOhort) study sought to assess the independent effect of using these drugs on subsequent mortality risk in patients with stable angina. Methods: Consecutive patients with stable angina, receiving at least one antianginal drug (nitrates, β-adrenoceptor antagonists, calcium channel antagonists, trimetazidine, or nicorandil), were selected if they were discharged alive from an intensive care unit following a myocardial infarction (MI). Their case-record data were used in a multivariate logistic regression model to examine the independent association of antianginal drug use prior to the MI with predicted post-discharge, 6-month, all-cause mortality risk. Results: In 353 patients, of whom 287 (81.3{\%}) were men, the mean (± SD) age was 55 (± 10.2) years and duration of treated stable angina was 27.2 (± 24.8) months. The odds ratios (95{\%} CI) of 6-month, all-cause mortality after surviving an MI were: for treatment that included a β-adrenoceptor antagonist, 0.63 (0.26, 1.52; p = 0.309); a calcium channel antagonist, 0.76 (0.12, 2.89; p = 0.638); a nitrate, 0.52 (0.26, 1.05; p = 0.070); nicorandil, 0.62 (0.29, 1.33; p = 0.221); and trimetazidine, 0.36 (0.15, 0.86; p = 0.022). Conclusion: The inclusion of trimetazidine in the antianginal treatment of stable angina is independently associated with a significant reduction in mortality after surviving an MI. This suggests that combining a metabolic agent with drugs that modulate oxygen supply and demand, early in the management of stable angina, may confer a survival benefit.",
author = "Iyengar, {Shamanna S.} and Rosano, {G. M C}",
year = "2009",
doi = "10.2165/11316840-000000000-00000",
language = "English",
volume = "9",
pages = "293--297",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction

T2 - A preliminary study (METRO)

AU - Iyengar, Shamanna S.

AU - Rosano, G. M C

PY - 2009

Y1 - 2009

N2 - Background: Although antianginal drugs are used over several months and through to years in stable angina, there is scant evidence regarding their influence on outcomes. The METRO (ManagEment of angina: a reTRospective cOhort) study sought to assess the independent effect of using these drugs on subsequent mortality risk in patients with stable angina. Methods: Consecutive patients with stable angina, receiving at least one antianginal drug (nitrates, β-adrenoceptor antagonists, calcium channel antagonists, trimetazidine, or nicorandil), were selected if they were discharged alive from an intensive care unit following a myocardial infarction (MI). Their case-record data were used in a multivariate logistic regression model to examine the independent association of antianginal drug use prior to the MI with predicted post-discharge, 6-month, all-cause mortality risk. Results: In 353 patients, of whom 287 (81.3%) were men, the mean (± SD) age was 55 (± 10.2) years and duration of treated stable angina was 27.2 (± 24.8) months. The odds ratios (95% CI) of 6-month, all-cause mortality after surviving an MI were: for treatment that included a β-adrenoceptor antagonist, 0.63 (0.26, 1.52; p = 0.309); a calcium channel antagonist, 0.76 (0.12, 2.89; p = 0.638); a nitrate, 0.52 (0.26, 1.05; p = 0.070); nicorandil, 0.62 (0.29, 1.33; p = 0.221); and trimetazidine, 0.36 (0.15, 0.86; p = 0.022). Conclusion: The inclusion of trimetazidine in the antianginal treatment of stable angina is independently associated with a significant reduction in mortality after surviving an MI. This suggests that combining a metabolic agent with drugs that modulate oxygen supply and demand, early in the management of stable angina, may confer a survival benefit.

AB - Background: Although antianginal drugs are used over several months and through to years in stable angina, there is scant evidence regarding their influence on outcomes. The METRO (ManagEment of angina: a reTRospective cOhort) study sought to assess the independent effect of using these drugs on subsequent mortality risk in patients with stable angina. Methods: Consecutive patients with stable angina, receiving at least one antianginal drug (nitrates, β-adrenoceptor antagonists, calcium channel antagonists, trimetazidine, or nicorandil), were selected if they were discharged alive from an intensive care unit following a myocardial infarction (MI). Their case-record data were used in a multivariate logistic regression model to examine the independent association of antianginal drug use prior to the MI with predicted post-discharge, 6-month, all-cause mortality risk. Results: In 353 patients, of whom 287 (81.3%) were men, the mean (± SD) age was 55 (± 10.2) years and duration of treated stable angina was 27.2 (± 24.8) months. The odds ratios (95% CI) of 6-month, all-cause mortality after surviving an MI were: for treatment that included a β-adrenoceptor antagonist, 0.63 (0.26, 1.52; p = 0.309); a calcium channel antagonist, 0.76 (0.12, 2.89; p = 0.638); a nitrate, 0.52 (0.26, 1.05; p = 0.070); nicorandil, 0.62 (0.29, 1.33; p = 0.221); and trimetazidine, 0.36 (0.15, 0.86; p = 0.022). Conclusion: The inclusion of trimetazidine in the antianginal treatment of stable angina is independently associated with a significant reduction in mortality after surviving an MI. This suggests that combining a metabolic agent with drugs that modulate oxygen supply and demand, early in the management of stable angina, may confer a survival benefit.

UR - http://www.scopus.com/inward/record.url?scp=70349755365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349755365&partnerID=8YFLogxK

U2 - 10.2165/11316840-000000000-00000

DO - 10.2165/11316840-000000000-00000

M3 - Article

C2 - 19791838

AN - SCOPUS:70349755365

VL - 9

SP - 293

EP - 297

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 5

ER -